<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03607539</url>
  </required_header>
  <id_info>
    <org_study_id>CIBI308C302</org_study_id>
    <nct_id>NCT03607539</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLC</brief_title>
  <official_title>A Randomized, Double-blinded, Phase III Study of Pemetrexed Plus Platinum Chemotherapy With or Without Sintilimab (IBI308) in First Line Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Subjects (Orient-11)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovent Biologics (Suzhou) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovent Biologics (Suzhou) Co. Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Efficacy and Safety Evaluation of IBI308 in Patients with advanced or metastatic Non-squamous&#xD;
      NSCLC&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sintilimab is expected to increase the PFS from 6 months to 9.2 months. Anti-PD-1 therapy in&#xD;
      Chinese non-squamous NSCLC naïve patients will be investigated in this clinical trial.&#xD;
&#xD;
      Additionally the correlation between PD-L1 expression and the response to Sintilimab&#xD;
      treatment in Chinese non-squamous NSCLC as well as the role of iRECIST in immune checkpoint&#xD;
      inhibitor treatment evaluation will also be assessed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 23, 2018</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Actual">November 15, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Independent Radiographic Review Committee (IRRC)</measure>
    <time_frame>Trough Database Cutoff Date of 15-Nov-2019 (Up to approximately 16 months)</time_frame>
    <description>PFS was defined as the time from randomization to the first documented PD or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Trough Database Cutoff Date of 15-Nov-2019 (Up to approximately 16 months)</time_frame>
    <description>The analysis population consisted of all randomized participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) by IRRC Assessment</measure>
    <time_frame>Trough Database Cutoff Date of 15-Nov-2019 (Up to approximately 16 months)</time_frame>
    <description>ORR was defined as the percentage of participants in the analysis population who had a confirmed CR (disappearance of all lesions) or PR (at least a 30% decrease in the sum of diameters [SOD] of target lesions, taking as reference the baseline SOD) according to RECIST 1.1, which was modified for this study to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ. The percentage of participants who experienced a confirmed CR or PR according to RECIST 1.1 as assessed by IRC was reported as the ORR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR) by IRRC Assessment</measure>
    <time_frame>Trough Database Cutoff Date of 15-Nov-2019 (Up to approximately 16 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response (TTR) by IRRC Assessment</measure>
    <time_frame>Trough Database Cutoff Date of 15-Nov-2019 (Up to approximately 16 months)</time_frame>
    <description>TTR was defined as the time of participants from the first treatment administration to the first incidence of a confirmed CR (disappearance of all lesions) or PR (at least a 30% decrease in the sum of diameters [SOD] of target lesions, taking as reference the baseline SOD) according to RECIST 1.1, which was modified for this study to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ. The time from first treatment administration to the first incidence of treatment response was reported as the TTR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) by IRRC Assessment</measure>
    <time_frame>From time of first documented evidence of CR or PR trough Database Cutoff Date of 15-Nov-2019 (Up to approximately 16 months)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">397</enrollment>
  <condition>Lung Neoplasms</condition>
  <arm_group>
    <arm_group_label>Sintilimab in combination with pemetrexed and platinum</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection; dosage form: 10ml: 100mg; frequency: 200mgQ3W (qualer 3 weeks); duration: randomization to the date of the first documented tumor progression per RECIST v1.1 criteria Sintilimab 200mg + pemetrexed/ platinum 4 cycles then Sintilimab 200mg + pemetrexed maintains</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sitilimab Placebo Comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo 2 vials + pemetrexed/ platinum 4 cycles then Sintilimab 200mg + pemetrexed maintains</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sintilimab</intervention_name>
    <description>10 mL:100 mg，200mg，Q3W (qualer 3 weeks), day1, I.V.</description>
    <arm_group_label>Sintilimab in combination with pemetrexed and platinum</arm_group_label>
    <other_name>IBI308</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>500mg/m^2; Q3W (qualer 3 weeks), day1, I.V.</description>
    <arm_group_label>Sintilimab in combination with pemetrexed and platinum</arm_group_label>
    <arm_group_label>Sitilimab Placebo Comparator</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Platinum</intervention_name>
    <description>Q3W (qualer 3 weeks), day1, I.V.; first 4 cycles.</description>
    <arm_group_label>Sintilimab in combination with pemetrexed and platinum</arm_group_label>
    <arm_group_label>Sitilimab Placebo Comparator</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>10 mL:100 mg，200mg，Q3W (qualer 3 weeks), day1, I.V.</description>
    <arm_group_label>Sitilimab Placebo Comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          1. Sign written informed consent before any trial-related processes are implemented;&#xD;
&#xD;
          2. Age ≥ 18 years and &lt;75 years;&#xD;
&#xD;
          3. Life expectancy exceeds 3 months;&#xD;
&#xD;
          4. The investigator confirmed at least one measurable lesion according to RECIST 1.1.&#xD;
&#xD;
             A measurable lesion located in the field of previous radiation therapy or after local&#xD;
             treatment may be selected as a target lesion if it is confirmed to have progressed;&#xD;
&#xD;
          5. According to the International Lung Cancer Research Association and the American&#xD;
             Association for the Classification of Cancer Classification, the 8th edition of the&#xD;
             TNM (Tumor Node Metastasis) staging of lung cancer, a histologically or cytologically&#xD;
             confirmed locally advanced (IIIB/IIIC phase) that cannot be treated surgically and&#xD;
             cannot undergo radical concurrent chemoradiotherapy, Patients with metastatic or&#xD;
             recurrent (stage IV) non-squamous NSCLC;&#xD;
&#xD;
          6. Confirmed for patients with EGFR (Epidermal growth factor receptor) or ALK (Anaplastic&#xD;
             lymphoma kinase) targeted therapy (documentary evidence of no tumor EGFR-sensitive&#xD;
             mutations and no ALK gene rearrangement)&#xD;
&#xD;
          7. The Eastern Cancer Cooperative Group (ECOG) has a performance score of 0 or 1;&#xD;
&#xD;
          8. Have not received any systematic anti-tumor treatment for advanced disease; The&#xD;
             patient may have received adjuvant chemotherapy as long as the disease relapses at&#xD;
             least 6 months after the last dose of chemotherapy is completed;&#xD;
&#xD;
          9. Adequate hematologic function, defined as absolute neutrophil count ≥1.5×10^9 /L,&#xD;
             platelet count ≥100 ×10^9 /L, hemoglobin ≥9g/dL (no blood transfusion or&#xD;
             erythropoietin (EPO) within 7 days) Dependency);&#xD;
&#xD;
         10. Adequate liver function, defined as total bilirubin levels ≤ 1.5 times normal upper&#xD;
             limit (ULN) and aspartate aminotransferase (AST) and alanine aminotransferase (ALT)&#xD;
             levels ≤ 2.5 times ULN in all patients, or for recorded liver Patients with&#xD;
             metastasis, AST and ALT levels ≤ 5 times ULN;&#xD;
&#xD;
         11. Adequate renal function, defined as serum creatinine ≤ 1.5 times ULN or measured or&#xD;
             calculated creatinine clearance ≥ 60 ml / min (Cockcroft-Gault formula);&#xD;
&#xD;
         12. Coagulation function is adequate, defined as international normalized ratio (INR) or&#xD;
             prothrombin time (PT) ≤ 1.5 times normal upper limit (ULN); if the subject is&#xD;
             receiving anticoagulant therapy, as long as the PT is used in anticoagulant drugs&#xD;
             Within the scope;&#xD;
&#xD;
         13. Female subjects of childbearing age should be negative for urine or serum pregnancy&#xD;
             test within 72 hours prior to the first study drug administration (Day 1, Day 1). If&#xD;
             the urine pregnancy test results are positive or cannot be confirmed as negative, a&#xD;
             blood pregnancy test is required.&#xD;
&#xD;
         14. If there is a risk of conception, male and female patients are required to use&#xD;
             high-efficiency contraception (ie, an annual failure rate of less than 1%) and&#xD;
             continue until at least 180 days after stopping the trial treatment; Note: If&#xD;
             abstinence is the usual lifestyle of the subject and the preferred method of&#xD;
             contraception, abstinence can be accepted as a method of contraception.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Histological squamous cell-dominated NSCLC; Mixed cell types must distinguish between&#xD;
             dominant cell morphology, and if small cell types are present, the subject is not&#xD;
             eligible for inclusion;&#xD;
&#xD;
          2. Currently participating in interventional clinical research or treatment, or receiving&#xD;
             other research drugs or using research equipment within 4 weeks before the first dose;&#xD;
&#xD;
          3. Previously received the following therapies: anti-PD-1, anti-PD-L1 or anti-PD-L2 drugs&#xD;
             or against another stimulatory or synergistic inhibition of T cell receptors [eg&#xD;
             CTLA-4 (Cytotoxic T lymphocyte antigen-4), OX-40 (also called CD134, cluster of&#xD;
             differentiation134), CD137] agent;&#xD;
&#xD;
          4. Received a traditional Chinese medicine with anti-tumor effect, or an immunomodulatory&#xD;
             drug (thymosin, interferon, interleukin) within 2 weeks before the first dose, or&#xD;
             received major surgery within 3 weeks before the first dose;&#xD;
&#xD;
          5. Pulmonary radiation therapy of &gt;30 Gy within 6 months prior to the first dose;&#xD;
&#xD;
          6. Completed palliative radiotherapy within 7 days prior to the first dose;&#xD;
&#xD;
          7. Clinical active diverticulitis, abdominal abscess, gastrointestinal obstruction and&#xD;
             peritoneal metastasis;&#xD;
&#xD;
          8. Have received a physical organ or blood system transplant;&#xD;
&#xD;
          9. There is clinically uncontrollable pleural effusion/peritoneal effusion;&#xD;
&#xD;
         10. known to have severe allergic reactions (≥3 grade) to the active ingredients of&#xD;
             Sintilimab, pemetrexed, cisplatin, carboplatin and or any excipients;&#xD;
&#xD;
         11. Active autoimmune diseases requiring systemic treatment (eg, using a disease-modifying&#xD;
             drug, corticosteroid or immunosuppressant) within 2 years prior to the first dose.&#xD;
             Alternative therapies (such as thyroxine, insulin, or physiological corticosteroids&#xD;
             for adrenal or pituitary insufficiency) are not considered systemic treatments;&#xD;
&#xD;
         12. Diagnosis of immunodeficiency or study of systemic steroid therapy or any other form&#xD;
             of immunosuppressive therapy within 7 days prior to the first dose of study.&#xD;
&#xD;
             Physiological doses of corticosteroids (≤10 mg/day of prednisone or equivalent) are&#xD;
             permitted;&#xD;
&#xD;
         13. Has not fully recovered from the toxicity and/or complications caused by any&#xD;
             intervention before starting treatment (ie, ≤1 or reaching baseline, excluding fatigue&#xD;
             or alopecia);&#xD;
&#xD;
         14. Other malignant tumors were diagnosed within 5 years prior to the first dose, with the&#xD;
             exception of radical cutaneous basal cell carcinoma, cutaneous squamous cell&#xD;
             carcinoma, and/or radically resected carcinoma in situ;&#xD;
&#xD;
         15. Active central nervous system (CNS) metastasis and / or cancerous meningitis. Patients&#xD;
             with treated brain metastases who have remained clinically stable for at least 2 weeks&#xD;
             and have no new or advanced brain metastases may be enrolled and discontinued hormone&#xD;
             therapy 3 days prior to the first study drug. Patients with known untreated,&#xD;
             asymptomatic brain metastases can be enrolled, but regular imaging assessments of the&#xD;
             brain must be performed.&#xD;
&#xD;
         16. There is a history of (non-infectious) pneumonia requiring steroid therapy or the&#xD;
             presence of interstitial lung disease 1 year before the first dose;&#xD;
&#xD;
         17. There are active infections that require systemic treatment;&#xD;
&#xD;
         18. Subjects who are unable or unwilling to receive folic acid or vitamin B12&#xD;
             supplementation;&#xD;
&#xD;
         19. There are known cases of mental illness or substance abuse that may have an impact on&#xD;
             compliance with the test requirements;&#xD;
&#xD;
         20. A history of human immunodeficiency virus (HIV) infection (ie, HIV 1/2 antibody&#xD;
             positive) is known.&#xD;
&#xD;
         21. Untreated active hepatitis B;&#xD;
&#xD;
             Note: Controlled (treated) hepatitis B subjects also meet the inclusion criteria if&#xD;
             the following criteria are met:&#xD;
&#xD;
             At least 4 weeks of HBV (Hepatitis B virus) antiviral therapy must have been received&#xD;
             prior to the first dose of study drug, and the HBV viral load is &lt;1000 copies/ml (200&#xD;
             IU/ml). Subjects who are receiving HBV therapy and have a viral load of &lt;1000&#xD;
             copies/ml (200 IU/ml) should receive antiviral therapy throughout the study treatment&#xD;
             period.&#xD;
&#xD;
             For subjects with anti-HBc (hepatitis B core antigen)(+), HBsAg(-), anti-HBs(-), and&#xD;
             HBV viral load (-), prophylactic anti-HBV therapy is not required, but viral&#xD;
             reactivation is closely monitored;&#xD;
&#xD;
         22. Active HCV (Hepatitis C virus)-infected subjects (HCV antibody positive and HCV-RNA&#xD;
             levels above the lower limit of detection);&#xD;
&#xD;
         23. Vaccination of live vaccine within 30 days before the first dose (1st cycle, 1st day);&#xD;
             Note: Inactivated virus vaccines for seasonal influenza, injectable drugs are&#xD;
             permitted; however, live attenuated influenza vaccines (such as FluMist®) are not&#xD;
             allowed for intranasal administration;&#xD;
&#xD;
         24. There may be a history of illness or disease evidence, treatment or laboratory&#xD;
             abnormalities that may interfere with the subject's full participation in the study,&#xD;
             or the investigator believes that participating in the study is not in the best&#xD;
             interests of the subject, including dialysis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li Zhang, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>SunYat-senUniversity</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sun Yat-Sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>July 12, 2018</study_first_submitted>
  <study_first_submitted_qc>July 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2018</study_first_posted>
  <results_first_submitted>November 30, 2020</results_first_submitted>
  <results_first_submitted_qc>January 27, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 16, 2021</results_first_posted>
  <last_update_submitted>January 27, 2021</last_update_submitted>
  <last_update_submitted_qc>January 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 9, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/39/NCT03607539/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sintilimab Combination</title>
          <description>Sintilimab 200mg, pemetrexed 500mg/m2, cisplatin 75mg/m2 or carboplatin AUC 5 IV infusion q3w for 4 cycles, then sintilimab 200mg, pemetrexed 500mg/m2 IV infusion q3w</description>
        </group>
        <group group_id="P2">
          <title>Placebo Combination</title>
          <description>Placebo 200mg, pemetrexed 500mg/m2, cisplatin 75mg/m2 or carboplatin AUC 5 IV infusion q3w for 4 cycles, then placebo, pemetrexed 500mg/m2 IV infusion q3w</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="266"/>
                <participants group_id="P2" count="131"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="266"/>
                <participants group_id="P2" count="131"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sintilimab Combination</title>
          <description>Sintilimab 200mg, pemetrexed 500mg/m2, cisplatin 75mg/m2 or carboplatin AUC 5 IV infusion q3w for 4 cycles, then sintilimab 200mg, pemetrexed 500mg/m2 IV infusion q3w</description>
        </group>
        <group group_id="B2">
          <title>Placebo Combination</title>
          <description>Placebo 200mg, pemetrexed 500mg/m2, cisplatin 75mg/m2 or carboplatin AUC 5 IV infusion q3w for 4 cycles, then placebo, pemetrexed 500mg/m2 IV infusion q3w</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="266"/>
            <count group_id="B2" value="131"/>
            <count group_id="B3" value="397"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.9" spread="8.35"/>
                    <measurement group_id="B2" value="59.5" spread="8.73"/>
                    <measurement group_id="B3" value="59.8" spread="8.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="94"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="204"/>
                    <measurement group_id="B2" value="99"/>
                    <measurement group_id="B3" value="303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="266"/>
                    <measurement group_id="B2" value="131"/>
                    <measurement group_id="B3" value="397"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Programmed Cell Death-Ligand(PD-L1) Tumor Proportion Score(TPS)</title>
          <description>Participants were assessed for their PD-L1 tumor expression level by immunohistochemistry assay using tumor tissue from an archival or newly obtained biopsy.&#xD;
Participants with a TPS ≥1% were classified as PD-L1 positive and participants with a TPS &lt;1% were classified as PD-L1 negative.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>PD-L1 &lt;1% (measured by the tumor proportion score [TPS])</title>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="129"/>
                  </measurement_list>
                </category>
                <category>
                  <title>PD-L1 ≥ 1% (measured by the tumor proportion score[TPS])</title>
                  <measurement_list>
                    <measurement group_id="B1" value="181"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Platinum Chemotherapy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Cisplatin</title>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="104"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Carboplatin</title>
                  <measurement_list>
                    <measurement group_id="B1" value="195"/>
                    <measurement group_id="B2" value="98"/>
                    <measurement group_id="B3" value="293"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Independent Radiographic Review Committee (IRRC)</title>
        <description>PFS was defined as the time from randomization to the first documented PD or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD</description>
        <time_frame>Trough Database Cutoff Date of 15-Nov-2019 (Up to approximately 16 months)</time_frame>
        <population>The analysis population consisted of all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Sintilimab Combination</title>
            <description>Sintilimab 200mg, pemetrexed 500mg/m2, cisplatin 75mg/m2 or carboplatin AUC 5 IV infusion q3w for 4 cycles, then sintilimab 200mg, pemetrexed 500mg/m2 IV infusion q3w</description>
          </group>
          <group group_id="O2">
            <title>Placebo Combination</title>
            <description>Placebo 200mg, pemetrexed 500mg/m2, cisplatin 75mg/m2 or carboplatin AUC 5 IV infusion q3w for 4 cycles, then placebo, pemetrexed 500mg/m2 IV infusion q3w</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Independent Radiographic Review Committee (IRRC)</title>
          <description>PFS was defined as the time from randomization to the first documented PD or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD</description>
          <population>The analysis population consisted of all randomized participants.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="266"/>
                <count group_id="O2" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9" lower_limit="7.1" upper_limit="11.3"/>
                    <measurement group_id="O2" value="5.0" lower_limit="4.8" upper_limit="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>The analysis population consisted of all randomized participants.</description>
        <time_frame>Trough Database Cutoff Date of 15-Nov-2019 (Up to approximately 16 months)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sintilimab Combination</title>
            <description>Sintilimab 200mg, pemetrexed 500mg/m2, cisplatin 75mg/m2 or carboplatin AUC 5 IV infusion q3w for 4 cycles, then sintilimab 200mg, pemetrexed 500mg/m2 IV infusion q3w</description>
          </group>
          <group group_id="O2">
            <title>Placebo Combination</title>
            <description>Placebo 200mg, pemetrexed 500mg/m2, cisplatin 75mg/m2 or carboplatin AUC 5 IV infusion q3w for 4 cycles, then placebo, pemetrexed 500mg/m2 IV infusion q3w</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>The analysis population consisted of all randomized participants.</description>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="266"/>
                <count group_id="O2" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Median OS and OS range lower and upper limit of 95% CI not reached</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="11.4" upper_limit="NA">Median OS and OS range upper limit of 95% CI not reached</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response Rate (ORR) by IRRC Assessment</title>
        <description>ORR was defined as the percentage of participants in the analysis population who had a confirmed CR (disappearance of all lesions) or PR (at least a 30% decrease in the sum of diameters [SOD] of target lesions, taking as reference the baseline SOD) according to RECIST 1.1, which was modified for this study to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ. The percentage of participants who experienced a confirmed CR or PR according to RECIST 1.1 as assessed by IRC was reported as the ORR</description>
        <time_frame>Trough Database Cutoff Date of 15-Nov-2019 (Up to approximately 16 months)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sintilimab Combination</title>
            <description>Sintilimab 200mg, pemetrexed 500mg/m2, cisplatin 75mg/m2 or carboplatin AUC 5 IV infusion q3w for 4 cycles, then sintilimab 200mg, pemetrexed 500mg/m2 IV infusion q3w</description>
          </group>
          <group group_id="O2">
            <title>Placebo Combination</title>
            <description>Placebo 200mg, pemetrexed 500mg/m2, cisplatin 75mg/m2 or carboplatin AUC 5 IV infusion q3w for 4 cycles, then placebo, pemetrexed 500mg/m2 IV infusion q3w</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate (ORR) by IRRC Assessment</title>
          <description>ORR was defined as the percentage of participants in the analysis population who had a confirmed CR (disappearance of all lesions) or PR (at least a 30% decrease in the sum of diameters [SOD] of target lesions, taking as reference the baseline SOD) according to RECIST 1.1, which was modified for this study to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ. The percentage of participants who experienced a confirmed CR or PR according to RECIST 1.1 as assessed by IRC was reported as the ORR</description>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="266"/>
                <count group_id="O2" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.9" lower_limit="45.70" upper_limit="58.02"/>
                    <measurement group_id="O2" value="29.8" lower_limit="22.10" upper_limit="38.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Control Rate (DCR) by IRRC Assessment</title>
        <time_frame>Trough Database Cutoff Date of 15-Nov-2019 (Up to approximately 16 months)</time_frame>
        <population>The analysis population consisted of all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Sintilimab Combination</title>
            <description>Sintilimab 200mg, pemetrexed 500mg/m2, cisplatin 75mg/m2 or carboplatin AUC 5 IV infusion q3w for 4 cycles, then sintilimab 200mg, pemetrexed 500mg/m2 IV infusion q3w</description>
          </group>
          <group group_id="O2">
            <title>Placebo Combination</title>
            <description>Placebo 200mg, pemetrexed 500mg/m2, cisplatin 75mg/m2 or carboplatin AUC 5 IV infusion q3w for 4 cycles, then placebo, pemetrexed 500mg/m2 IV infusion q3w</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Control Rate (DCR) by IRRC Assessment</title>
          <population>The analysis population consisted of all randomized participants.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="266"/>
                <count group_id="O2" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.8" lower_limit="82.18" upper_limit="90.66"/>
                    <measurement group_id="O2" value="75.6" lower_limit="67.30" upper_limit="82.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Response (TTR) by IRRC Assessment</title>
        <description>TTR was defined as the time of participants from the first treatment administration to the first incidence of a confirmed CR (disappearance of all lesions) or PR (at least a 30% decrease in the sum of diameters [SOD] of target lesions, taking as reference the baseline SOD) according to RECIST 1.1, which was modified for this study to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ. The time from first treatment administration to the first incidence of treatment response was reported as the TTR</description>
        <time_frame>Trough Database Cutoff Date of 15-Nov-2019 (Up to approximately 16 months)</time_frame>
        <population>The analysis population consisted of all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Sintilimab Combination</title>
            <description>Sintilimab 200mg, pemetrexed 500mg/m2, cisplatin 75mg/m2 or carboplatin AUC 5 IV infusion q3w for 4 cycles, then sintilimab 200mg, pemetrexed 500mg/m2 IV infusion q3w</description>
          </group>
          <group group_id="O2">
            <title>Placebo Combination</title>
            <description>Placebo 200mg, pemetrexed 500mg/m2, cisplatin 75mg/m2 or carboplatin AUC 5 IV infusion q3w for 4 cycles, then placebo, pemetrexed 500mg/m2 IV infusion q3w</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Response (TTR) by IRRC Assessment</title>
          <description>TTR was defined as the time of participants from the first treatment administration to the first incidence of a confirmed CR (disappearance of all lesions) or PR (at least a 30% decrease in the sum of diameters [SOD] of target lesions, taking as reference the baseline SOD) according to RECIST 1.1, which was modified for this study to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ. The time from first treatment administration to the first incidence of treatment response was reported as the TTR</description>
          <population>The analysis population consisted of all randomized participants.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="266"/>
                <count group_id="O2" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.51" lower_limit="1.2" upper_limit="7.0"/>
                    <measurement group_id="O2" value="2.63" lower_limit="1.2" upper_limit="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response (DOR) by IRRC Assessment</title>
        <time_frame>From time of first documented evidence of CR or PR trough Database Cutoff Date of 15-Nov-2019 (Up to approximately 16 months)</time_frame>
        <population>The analysis population consisted of all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Sintilimab Combination</title>
            <description>Sintilimab 200mg, pemetrexed 500mg/m2, cisplatin 75mg/m2 or carboplatin AUC 5 IV infusion q3w for 4 cycles, then sintilimab 200mg, pemetrexed 500mg/m2 IV infusion q3w</description>
          </group>
          <group group_id="O2">
            <title>Placebo Combination</title>
            <description>Placebo 200mg, pemetrexed 500mg/m2, cisplatin 75mg/m2 or carboplatin AUC 5 IV infusion q3w for 4 cycles, then placebo, pemetrexed 500mg/m2 IV infusion q3w</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response (DOR) by IRRC Assessment</title>
          <population>The analysis population consisted of all randomized participants.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="266"/>
                <count group_id="O2" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="7.98" upper_limit="NA">Median DOR and DOR range upper limit of 95% CI not reached</measurement>
                    <measurement group_id="O2" value="5.52" lower_limit="4.14" upper_limit="10.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Trough Database Cutoff Date of 15-Nov-2019 (Up to approximately 16 months)</time_frame>
      <desc>The incidence (frequency) and severity (according to NCI CTCAE Version 4.03) of adverse events (AEs). Population: All participants receiving ≥1 dose of randomized study drug. All adverse events, including serious adverse events, will be collected since the consent form is signed until 90th day after last administration of investigation products, either observed by investigator or by the spontaneous reported by subjects.</desc>
      <group_list>
        <group group_id="E1">
          <title>Sintilimab Combination</title>
          <description>Sintilimab 200mg, pemetrexed 500mg/m2, cisplatin 75mg/m2 or carboplatin AUC 5 IV infusion q3w for 4 cycles, then sintilimab 200mg, pemetrexed 500mg/m2 IV infusion q3w</description>
        </group>
        <group group_id="E2">
          <title>Placebo Combination</title>
          <description>Placebo 200mg, pemetrexed 500mg/m2, cisplatin 75mg/m2 or carboplatin AUC 5 IV infusion q3w for 4 cycles, then placebo, pemetrexed 500mg/m2 IV infusion q3w</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Cardiovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Immune-mediated myocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Pericarditis constrictive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Febrile infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Purulent pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Enteritis infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Infectious pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Myelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Peripheral nerve infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Acid base balance abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Eosinophil count increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Troponin I increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Hypophagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Hypoproteinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Brain oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Cerebral artery embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Immune-mediated pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Asphyxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Obstructive airways disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Henoch-Schonlein purpura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Toxic epidermal necrolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Dermatomyositis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Embolism arterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Superior vena cava syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="265" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="131" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="197" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="103" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="108" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="87" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="189" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="180" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="84" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="113" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="109" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="108" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Blood thyroid stimulating hormone increased</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="101" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Hypophagia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Hypoproteinaemia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Tachypnoea</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Yi Bo</name_or_title>
      <organization>Innovent Biologics (Suzhou) Co., Ltd. (seal)</organization>
      <phone>+8613382419112</phone>
      <email>jessica.yi@innoventbio.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

